Evidence for dopaminergic control of aldosterone in man.
The effect of L-dopa (0.50 g, orally) on serum aldosterone, cortisol and potassium levels, plasma renin activity, and on urinary aldosterone excretion has been studied in normotensive subjects, before and after dexamethasone-induced ACTH suppression. L-dopa caused a further reduction in the levels of aldosterone but not cortisol, in the dexamethasone treated subjects. It is therefore suggested that the inhibitory action of L-dopa on aldosterone secretion is mediated by the dopaminergic system.
D000328:Adult; D000450:Aldosterone / Q000097:blood / Q000378:metabolism* / Q000652:urine; D003907:Dexamethasone / Q000494:pharmacology; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007980:Levodopa / Q000494:pharmacology*; D008297:Male; D011188:Potassium / Q000097:blood; D012083:Renin / Q000097:blood
D007980:Levodopa; D000450:Aldosterone; D003907:Dexamethasone; D012083:Renin; D011188:Potassium; D006854:Hydrocortisone